Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study

Risk of clinically significant prostate adenocarcinoma (CaP) varies worldwide, although there is a uniform prevalence of latent disease. A hormone-responsive tissue, the prostate possesses the metabolizing capacity to biotransform a variety of environmental procarcinogens or endogenous hormones. Whe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Singh, Paras B., Ragavan, Narasimhan, Ashton, Katherine M., Basu, Prabir, Nadeem, Sayeed M., Nicholson, Caroline M., Krishna, R. K. Gopala, Matanhelia, Shyam S., Martin, Francis L.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2010
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3739086/
https://ncbi.nlm.nih.gov/pubmed/19935673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aja.2009.71
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares